Show simple item record

dc.contributor.authorBencherif, Sidi
dc.contributor.authorSands, R. Warren
dc.contributor.authorAli, Omar
dc.contributor.authorLi, Weiwei
dc.contributor.authorLewin, Sarah
dc.contributor.authorBraschler, Thomas
dc.contributor.authorTing-Y.S. Shih
dc.contributor.authorVerbeke, Catia
dc.contributor.authorBhatta, Deen
dc.contributor.authorDranoff, Glenn
dc.contributor.authorMooney, David
dc.date.accessioned2019-10-11T12:29:59Z
dc.date.issued2015
dc.identifier.citationBencherif, Sidi A., R. Warren Sands, Omar A. Ali, Weiwei A. Li, Sarah A. Lewin, Thomas M. Braschler, Ting-Yu Shih, et al. 2015. “Injectable Cryogel-Based Whole-Cell Cancer Vaccines.” Nature Communications6 (1): 7556. https://doi.org/10.1038/ncomms8556.
dc.identifier.issn2041-1723
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:41534545*
dc.description.abstractA biomaterial-based vaccination system that uses minimal extracorporeal manipulation could provide in situ enhancement of dendritic cell (DC) numbers, a physical space where DCs interface with transplanted tumour cells, and an immunogenic context. Here we encapsulate GM-CSF, serving as a DC enhancement factor, and CpG ODN, serving as a DC activating factor, into sponge-like macroporous cryogels. These cryogels are injected subcutaneously into mice to localize transplanted tumour cells and deliver immunomodulatory factors in a controlled spatio-temporal manner. These vaccines elicit local infiltrates composed of conventional and plasmacytoid DCs, with the subsequent induction of potent, durable and specific anti-tumour T-cell responses in a melanoma model. These cryogels can be delivered in a minimally invasive manner, bypass the need for genetic modification of transplanted cancer cells and provide sustained release of immunomodulators. Altogether, these findings indicate the potential for cryogels to serve as a platform for cancer cell vaccinations.
dc.language.isoen_US
dc.publisherNature Research (part of Springer Nature)
dash.licenseLAA
dc.titleInjectable Cryogel-based Whole Cell Cancer Vaccines
dc.typeJournal Article
dc.description.versionVersion of Record
dc.relation.journalNature Communications
dash.depositing.authorMooney, David J.::00c54b0f354c5323ace343918ccde92e::600
dc.date.available2019-10-11T12:29:59Z
dash.workflow.comments1Science Serial ID 73041
dc.identifier.doi10.1038/ncomms8556
dash.source.volume6
dash.source.page7556


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record